

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-18. (Canceled)

19. (Currently Amended) The method according to claim ~~18-29~~ wherein said cancer is selected from the group consisting of melanoma, non-Hodgkin's lymphoma, cutaneous T cell lymphoma, Hodgkin's disease, leukemia, plasmocytoma, sarcoma, glioma, thymoma, breast cancer, prostate cancer, colo-rectal cancer, kidney cancer, renal cell carcinoma, uterine cancer, pancreatic cancer, esophageal cancer, brain cancer, lung cancer, ovarian cancer, cervical cancer, testicular cancer, gastric cancer, esophageal cancer, multiple myeloma, hepatoma, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL).

20. (Currently Amended) The method according to claim ~~18-29~~ wherein said cancer comprises multiple myeloma.

21. (Currently Amended) The method according to claim ~~18-29~~ wherein said cancer comprises CLL.

22. (Original) A method for activating and expanding a population of regulatory T cells by cell surface moiety ligation, comprising:

a. providing a population of cells wherein at least a portion thereof comprises regulatory T cells;

b. contacting said population of cells with a surface, wherein said surface has attached thereto a first agent that ligates a first T cell surface moiety of a regulatory T cell, and the same or a second surface has attached thereto a second agent that ligates a second moiety of

said regulatory T cell, wherein said ligation by the first and second agent induces proliferation of said regulatory T cell.

23. (Original) The method according to claim 22 wherein the first agent is an anti-CD3 antibody and the second agent is an anti-CD28 antibody.

24. (Canceled)

25. (Currently Amended) A composition comprising a population of T cells according to ~~any one of claims 1-16 and~~ 22 wherein said population of cells wherein at least a portion thereof comprises T cells is collected from a healthy individual for use at a later time point for the treatment of cancer in said individual.

26. (Currently Amended) The composition of ~~any one of claims 24-25~~ wherein said cancer is selected from the group consisting of melanoma, non-Hodgkin's lymphoma, cutaneous T cell lymphoma, Hodgkin's disease, leukemia, plasmacytoma, sarcoma, glioma, thymoma, breast cancer, prostate cancer, colo-rectal cancer, kidney cancer, renal cell carcinoma, uterine cancer, pancreatic cancer, esophageal cancer, brain cancer, lung cancer, ovarian cancer, cervical cancer, testicular cancer, gastric cancer, esophageal cancer, multiple myeloma, hepatoma, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL).

27. (Original) The method according to claim 26 wherein said cancer comprises multiple myeloma.

28. (Original) The method according to claim 26 wherein said cancer comprises CLL.

29. (New) A method for treating a cancer comprising:

a. contacting a population of cells obtained from a patient, wherein at least a portion of said population comprises T cells, with a surface, wherein said surface has attached thereto a first agent that ligates a first cell surface moiety of a T cell, and the same surface has attached thereto a second agent that ligates a second moiety of said T cell, wherein said ligation by the first and second agent induces proliferation of said T cell, and wherein said surface is present at a ratio of said surface to said cells such that at least one population of antigen-specific T cells is expanded at least about 10 fold in about 8 days;

b. administering to said patient the population of T cells from (a); and thereby treating the cancer.